All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
C-type lectin domain family 12 member A (CLEC12A), also called C-type lectin-like molecule 1 (CLL1), dendritic cell-associated lectin 2 (DCAL-2), myeloid inhibitory C-type lectin-like receptor (MICL) or CD371, is a protein encoded by the CLEC12A gene, which is a member of C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. CLEC12A has divers function of cell adhesion, cell-cell signalling, glycoprotein turnover, and roles in inflammation and immune response. CLEC12A is associated with leukemia.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
XS-0722-ZP4441 | Anti-CLEC12A (ch28H12) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | ch28H12 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-ZP4442 | Anti-CLEC12A (ch20Bl) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | ch20Bl | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-ZP4443 | Anti-CLEC12A (ch6E7) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | ch6E7 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0722-ZP4444 | Anti-CLEC12A (1075.7) h(CD28-CD3ζ) CAR, pCDCAR1 | Human | 1075.7 | Human | scFv-CD28-CD3ζ | Lentiviral vector | T cell | ||
XS-0822-YF2131 | Anti-Human CLEC12A (XW-291) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-291 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-0822-YF2132 | Anti-Human CLEC12A (XW-292) h(CD28-41BB-CD3ζ) CAR IVT Plasmid, pCARIVT | Human | XW-292 | Mouse | scFv-CD28-41BB-CD3ζ | In Vitro Transcription (IVT) Vector | |||
XS-1122-YF291 | Anti-CLEC12A KIR CAR (scFv-KIR2DS2-DAP12, M26), pCDCAR1 | Human | M26 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF292 | Anti-CLEC12A KIR CAR (scFv-KIR2DS2-DAP12, 1075.7), pCDCAR1 | Human | 1075.7 | Mouse | scFv-KIR2DS2 TM&ICD-2A-DAP12 | Lentiviral vector | T Cell | ||
XS-1122-YF1211 | Anti-CLEC12A TCR-ABR (scFv-TCRα, M26) CAR Plasmid, pCDCAR1 | Human | M26 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
XS-1122-YF1212 | Anti-CLEC12A TCR-ABR (scFv-TCRα, 1075.7) CAR Plasmid, pCDCAR1 | Human | 1075.7 | Mouse | scFv-TCRα | Lentiviral vector | T Cell | ||
XS-1122-YF2131 | Anti-CLEC12A TCR-ABR (scFv-TCRβ, M26) CAR Plasmid, pCDCAR1 | Human | M26 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
XS-1122-YF2132 | Anti-CLEC12A TCR-ABR (scFv-TCRβ, 1075.7) CAR Plasmid, pCDCAR1 | Human | 1075.7 | Mouse | scFv-TCRβ | Lentiviral vector | T Cell | ||
XS-1122-YF3051 | Anti-CLEC12A TCR-ABR (scFv-CD3γ, M26) CAR Plasmid, pCDCAR1 | Human | M26 | Mouse | scFv-CD3γ | Lentiviral vector | T Cell | ||
XS-1122-YF3052 | Anti-CLEC12A TCR-ABR (scFv-CD3γ, 1075.7) CAR Plasmid, pCDCAR1 | Human | 1075.7 | Mouse | scFv-CD3γ | Lentiviral vector | T Cell | ||
XS-1122-YF3971 | Anti-CLEC12A TCR-ABR (scFv-CD3δ, M26) CAR Plasmid, pCDCAR1 | Human | M26 | Mouse | scFv-CD3δ | Lentiviral vector | T Cell | ||
XS-1122-YF3972 | Anti-CLEC12A TCR-ABR (scFv-CD3δ, 1075.7) CAR Plasmid, pCDCAR1 | Human | 1075.7 | Mouse | scFv-CD3δ | Lentiviral vector | T Cell | ||
XS-1122-YF4891 | Anti-CLEC12A TCR-ABR (scFv-CD3ε, M26) CAR Plasmid, pCDCAR1 | Human | M26 | Mouse | scFv-CD3ε | Lentiviral vector | T Cell | ||
XS-1122-YF4892 | Anti-CLEC12A TCR-ABR (scFv-CD3ε, 1075.7) CAR Plasmid, pCDCAR1 | Human | 1075.7 | Mouse | scFv-CD3ε | Lentiviral vector | T Cell | ||
XS-1122-YF5811 | Anti-CLEC12A (M26) h(CD28-CD3ζ) CAR, pAAV | Human | M26 | Mouse | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell | ||
XS-1122-YF5812 | Anti-CLEC12A (1075.7) h(CD28-CD3ζ) CAR, pAAV | Human | 1075.7 | Mouse | scFv-CD28-CD3ζ | Adeno-associated viral (AAV) vector | T Cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION